Pure Global
NCT04213313

Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis

Consecutive, Case Control Study of Association Between Single Nucleotide Polymorphism of SP-D and Susceptibility and Prognosis of Infectious Keratitis
Second Affiliated Hospital, School of Medicine, Zhejiang University·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Infectious Keratitis
Drug/Device/Intervention
Treatment of bacterial keratitis
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Location
Hangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2016
End date
Jun 30, 2019
Enrollment
145 participants
Primary outcome

Base type,Genotype

Summary

This study explores the association between single nucleotide polymorphism (Met11Thr) of
 surfactant protein D(SP-D) and susceptibility and prognosis of infectious keratitis.Met11Thr
 of SP-D of patients with keratitis and normal controls were compared.Allele and genotype
 frequencies of patients with keratitis and normal controls were determined by polymerase
 chain reaction with sequence specific primers(PCR-SSPs) .SP-D gene polymorphism of patients
 with keratitis and normal controls was detected by Sanger sequencing

ICD-10 classifications
KeratitisKeratitis, unspecifiedOther keratitisHerpesviral keratitis and keratoconjunctivitisKeratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04213313
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04213313 through Pure Global AI's free database. This phase not specified trial is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University and is currently Completed. The study focuses on Infectious Keratitis. Target enrollment is 145 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.